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Abstract
Introduction:  Predictive genetic screening and regular screening programs in patients with
multiple endocrine neoplasia type 1 are intended to detect and treat malignant tumors at the
earliest stage possible. Malignant neuroendocrine pancreatic tumors are the most frequent cause
of death in these patients. However, the extent and intervals of screening in patients with multiple
endocrine neoplasia type 1 are controversial as neuroendocrine tumors are usually slow growing.
Here we report the case of a patient who developed a fast-growing neuroendocrine carcinoma
within 15 months of a laparoscopic distal pancreatic resection.
Case presentation: We followed a group of 45 patients with multiple endocrine neoplasia type
1 by an annual screening program in the Department of Visceral, Thoracic, and Vascular Surgery at
the University Hospital Marburg in cooperation with the Department of Radiology and the Division
of Endocrinology. A man with multiple endocrine neoplasia type 1 who was diagnosed with a
recurrent primary hyperparathyroidism underwent a distal pancreatic resection for a non-
functional neuroendocrine tumor. In the context of our regular screening program, a large non-
functional neuroendocrine tumor was diagnosed in the pancreatic head 15 months after the first
pancreatic surgery. Therefore, we performed an enucleation and regional lymph node resection.
At histology, the diagnosis of a neuroendocrine carcinoma with one lymph node metastasis was
established. There was no evidence of recurrence 9 months after re-operation.
Conclusion: Fast-growing neuroendocrine tumors are rare in patients with multiple endocrine
neoplasia type 1. The intervals, both postoperative and in newly diagnosed pancreatic lesions, in
patients with multiple endocrine neoplasia type 1 should be reduced to 6 months to establish the
early diagnosis of rapidly progressive disease in a small subset of patients.
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Introduction
Multiple endocrine neoplasia type 1 syndrome (MEN1) is
an inherited tumor syndrome, which is typically charac-
terized by tumors of the parathyroid glands, the pancreas
and the pituitary. Organs such as the adrenal glands, the
thymus, the skin and the bronchial tree are involved less
frequently [1-4]. Pancreatoduodenal endocrine tumors
(PETs) are determinants of long-term survival. About one-
third of patients with MEN1 develop malignant tumors
[5,6]. Predictive genetic screening and regular screening
programs are designed to detect and treat malignant
tumors at the earliest stage possible. However, the extent
and intervals of screening in patients with MEN1 are con-
troversial. Current recommendations are based on the
National Institutes of Health (NIH) consensus conference
in 2001 [7]. A yearly biochemical screening and a tumor
imaging every 3 to 5 years are emphasized. In the past few
years, endoscopic ultrasound has gained importance in
the detection of PETs [8,9], particularly in the setting of a
prospective screening program. To date, the survival ben-
efit of periodic screening and early intervention has not
been proven.
As a consequence of periodic screening, asymptomatic
patients with functioning or non-functioning tumors are
scheduled for pancreatic resections more often and at a
younger age. The indication, extent and timing of surgery
in patients with MEN1 are a matter of debate. Indications
for insulinomas and non-functioning tumors larger than
2 cm are well established, although some groups postu-
late a more aggressive strategy with a limit of 10 mm in
non-functioning pancreatoduodenal endocrine tumors
(nf PETs) in order to prevent malignancy and liver metas-
tases [10-12]. Malignancy is evident in about one-half of
patients with PETs; unfortunately, markers for the devel-
opment or progression of malignant disease are not yet
available.
Here we report the case of a 37-year-old man with MEN1
who developed a rapidly growing non-functioning tumor
in the pancreatic remnant 15 months after a laparoscopic
distal pancreatic resection. To the best of the authors'
knowledge, this is the first report of a rapidly growing
non-functioning PET in a patient with MEN1 that was
detected by a regular screening program.
Case presentation
A 37-year-old man was diagnosed with MEN1 owing to a
recurrent symptomatic primary hyperparathyroidism
(pHPT) and a positive family history. Genetic analysis of
the Menin gene showed a frame-shift mutation in codon
229 (c.657 1bpdel/K285X). At the initial evaluation, a
non-functioning pituitary gland tumor, non-functioning
adrenal lesions and a 17 mm non-functioning PET were
detected. Normal levels of pancreatic polypeptide, gastrin,
chromogranin A, serotonin, insulin, proinsulin and gluca-
gon were present. Computed tomography (CT) showed a
tumor in the pancreatic tail with a diameter of 25 mm
without any radiological signs of malignancy. Endoscopic
ultrasound (EUS) visualized two small lesions in the pan-
creatic tail (Figure 1A). Somatostatin-receptor scintigra-
phy (SRS) did not provide any evidence of a somatostatin-
receptor positive tumor. There was no evidence of lymph
node metastases (LNMs) or distant metastases (DMs) in
the imaging procedures.
This patient was scheduled for a laparoscopic distal pan-
creatic resection after laparoscopic ultrasound (LUS) to
rule out additional tumors in the pancreatic head and
body. At laparoscopy, after mobilization of the pancreatic
tail, LUS confirmed the finding of the pre-operative EUS.
In the absence of additional lesions in the pancreatic head
and body, as well as no DMs or LNMs, the patient under-
went a spleen-preserving distal pancreatic resection. A
rapid histological diagnosis was performed to exclude
malignancy. Seven days after an uneventful clinical
course, the patient was discharged.
Histopathological examination showed four well-differ-
entiated neuroendocrine tumors (one of 40 mm, three of
3 mm). Immunohistochemistry displayed a positive
staining for synaptophysin and chromogranin A. The Ki-
67 index was lower than 1% (Figure 2A).
The patient was re-evaluated 15 months after surgery. At
presentation, the patient was asymptomatic. Thus, he par-
ticipated in our regular screening program and magnetic
resonance imaging (MRI), SRS and EUS were performed.
As was the case before the initial operation, hormone lev-
els were within the normal range. Surprisingly, MRI and
EUS demonstrated a tumor measuring 25 mm in the pan-
creatic head and an enlarged lymph node (LN) above the
caval vein on the lower pancreatic margin. DMs were not
detected. An additional pancreatic lesion, 7 mm in diam-
eter, was visualized by EUS (Figure 1B). The pancreatic
head tumor had developed within 12 months of surgery,
but radiological signs of invasion could not be estab-
lished. The patient was scheduled for surgical exploration
as malignancy was suspected owing to the rapid growth.
At laparotomy, an intra-operative ultrasound (IOUS) was
performed (Figure 3A). A well-outlined encapsulated
tumor measuring 22 mm was found in the pancreatic
head. Before the final decision on the surgical procedure
was made, one enlarged, but soft, LN of 15 mm from the
hepatic ligament was transected to rule out LNMs. As
rapid histological diagnosis showed a normal LN, the
pancreatic head tumor was enucleated. At the lower mar-
gin of the pancreatic head, two enlarged LNs of 10 mm
were also transected. The tumor bore macroscopic inva-Journal of Medical Case Reports 2008, 2:354 http://www.jmedicalcasereports.com/content/2/1/354
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sion of the surrounding pancreatic tissue. The defect was
covered by a Y-en-Roux loop (Figure 3B). A resection of
the pancreatic head would have resulted in a pancreatec-
tomy, which results in XXX pancreoprivic diabetes. The
patient was discharged after an uneventful clinical course
of 10 days.
Gross examination showed a pale tumor 28 mm in diam-
eter and a smooth, lobulated cut surface. The tumor was
covered by a white capsule (Figure 3C). Microscopically,
the tumor-forming epithelial glands infiltrated the pan-
creatic tissue. The tumor cells showed a hyperchromatic
nucleus with a gross chromatin structure. In some parts,
the tumor displayed necrosis. Immunohistochemistry
resulted in a positive staining for chromogranin A and a
negative staining for insulin and gastrin. The Ki-67 index
was again lower than 1%. The LN of the hepatic ligament
(12 mm) and one of the two LNs of the lower pancreatic
margin (10 mm) were without evidence of tumor cells.
The second LN of the lower pancreatic margin, measuring
9 mm, revealed an infiltration of atypical epithelial cells.
Discussion
In our experience with more than 40 patients who partic-
ipate in a regular screening program at our hospital, this is
an extraordinary case. Most non-functioning PETs in
patients with MEN1 are small, multiple and follow a
benign course and, consequently, are seen as slow-grow-
ing tumors [13].
Imaging studies before initial and re-operation Figure 1
Imaging studies before initial and re-operation. (A) Pre-operative computed tomography scan before the initial opera-
tion. (B) Pre-operative endoscopic ultrasound before the initial operation (asterisk indicates the tumor; Proc. unc., normal 
appearing uncinate process). (C) Pre-operative computed tomography scan before the re-operation. (D) Pre-operative endo-
scopic ultrasound before the re-operation.Journal of Medical Case Reports 2008, 2:354 http://www.jmedicalcasereports.com/content/2/1/354
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It is noteworthy that malignant PETs have become the
most important determinant of long-term survival [5,6].
About one-third of patients with MEN1 succumb to
malignant tumors. To date, no markers for malignancy
have been established. As a consequence, the rationale for
screening is to detect lesions at an earlier stage and to per-
form prophylactic, but pancreas-preserving, surgery
before DMs or LNMs develop. Predictive genetic screening
and regular screening programs are intended to detect and
treat malignant tumors at the earliest stage possible. How-
ever, the extent and intervals of screening in patients with
MEN1 are controversial owing to the fact that a survival
benefit of periodic screening and early intervention has
not been proven. Most authors emphasize a postoperative
follow-up after 12 months [14]. The Uppsala group and
the NIH consensus conference suggest a regular screening
interval of 3 to 5 years [7,15].
In view of the presented case, the diagnosis of a new, rap-
idly growing neuroendocrine carcinoma was established
in an asymptomatic patient as a result of a postoperative
follow-up at 15 months. A misdiagnosis and oversight by
three different imaging modalities (CT, EUS and IOUS)
before the initial surgery seem to be unlikely. A 6-month
follow-up in our patient would possibly have resulted in
earlier surgery on a smaller tumor. Therefore, we suggest a
closer follow-up every 6 to 12 months, postoperatively in
the case of a newly diagnosed lesion, taking into consider-
Histological characteristics of the neuroendocrine tumor at initial operation and the neuroendocrine carcinoma of the pan- creas at re-operation Figure 2
Histological characteristics of the neuroendocrine tumor at initial operation and the neuroendocrine carci-
noma of the pancreas at re-operation. (A) Hematoxylin and eosin stain of the large neuroendocrine tumor at the initial 
operation. (B) Ki-67 stain of the large neuroendocrine tumor at the initial operation. (C) Hematoxylin and eosin stain of the 
neuroendocrine carcinoma at re-operation. (D) Ki-67 stain of the neuroendocrine carcinoma at re-operation.Journal of Medical Case Reports 2008, 2:354 http://www.jmedicalcasereports.com/content/2/1/354
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ation that a small subset of patients seems to develop rap-
idly progressive disease. However, this policy leads to a
higher number of 'unnecessary investigations' in patients
who follow a benign course. Once patients display stable
disease over several years, the intervals may be extended.
Prospective data on follow-up of PETs in patients with
MEN1 are rare, and most studies did not differentiate
between prospective and non-prospective diagnosed
PETs. However, randomized prospective studies seem to
be unethical owing to the potential benefit of regular
screening.
The indication for surgery in patients with MEN1 is an
unresolved controversy. The observation that non-func-
tioning PETs smaller than 3 cm rarely developed LNMs
and DMs has prompted some groups to suggest operating
only on PETs larger than 3 cm. However, one could argue
that the aim is not to detect but to prevent metastases,
which leads to a more aggressive strategy and indicates
surgery when a PET larger than 10 mm is detected. Skog-
seid and Oberg emphasize performing surgery when bio-
chemical evidence is established with or without positive
imaging results [10].
The extent of surgery in non-functioning PETs is contro-
versial, although distal pancreatic resection up to the level
of the portal vein and enucleation of pancreatic head
tumors including LN transection is the procedure most
groups prefer. Laparoscopic resection could also be con-
sidered, simply because there are no data on the value of
routine LN dissection, notably in the setting of early sur-
gery in small non-functioning PETs. Whenever a re-opera-
Situs at laparotomy before and after resection Figure 3
Situs at laparotomy before and after resection. (A) Intra-operative ultrasound at laparotomy. (B) Situs at laparotomy 
(asterisk indicates the tumor; S, stomach; P, pylorus; PH, pancreatic head; D, duodenum). (C)Macroscopic view of the resected 
tumor. (D) Covering of the defect after resection by a Y-en-Roux jejunal loop.Journal of Medical Case Reports 2008, 2:354 http://www.jmedicalcasereports.com/content/2/1/354
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tion is indicated, the strategy must be tailored to the
patient, which makes it difficult to establish 'guidelines':
the younger the patient is, the more pancreatic tissue must
be preserved to prevent XXXpancreoprivic diabetes. In eld-
erly patient or in patients who present with diabetes, even
pancreatectomy is sometimes indicated, for example, after
a distal pancreatic resection when the tumor is located in
the pancreatic head. The location, number and size of
tumors must be taken into consideration to 'design' tai-
lored surgery in patients with MEN1.
Whenever dealing with prophylactic surgery, low morbid-
ity and almost absent mortality is required. It has to be
emphasized that most patients with non-functioning
PETs are asymptomatic and have excellent long-term sur-
vival without surgery. Therefore, total pancreatectomy is
rarely indicated but has been advocated for patients in
families with aggressive PETs. In our experience, it must
be considered that most patients who have undergone
pancreatic resection are discovered in the follow-up to
have developed small non-functioning PETs, which
would lead to additional surgery in the future. Patients
with a prior distal pancreatectomy would consequently
undergo a total pancreatectomy. The XXXpancreoprivic
severe diabetes in a patient of 40 or 50 years is of utmost
importance.
The patient we have presented here was scheduled for an
exploration, which could have resulted in either an enu-
cleation or a pancreatoduodenectomy. A resection of the
pancreatic head preserving the duodenum was also an
option. After the rapid section of the LN in the hepatic lig-
ament excluded LNMs, we decided on an enucleation of
the soft PET in the pancreatic head. Surprisingly, one LN,
macroscopically unsuspicious, at the lower margin was an
LNM. We will follow the patient closely and if he displays
evidence for local recurrence, he will be scheduled for
total pancreatectomy. Six months after surgery, he was
without any evidence of recurrence.
Conclusion
The postoperative follow-up intervals and those for newly
diagnosed pancreatic lesions should be reduced to 6
months to establish diagnosis as soon as possible in
patients with rapidly progressing disease.
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